Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemiaKEUNG, Yi-Kong; BUSS, David; POWELL, Bayard L et al.Cancer genetics and cytogenetics. 2002, Vol 136, Num 1, pp 78-81, issn 0165-4608Article

Constitutional pericentric inversion of chromosome 9 and acute leukemiaKEUNG, Yi-Kong; KNOVICH, Mary Ann; POWELL, Bayard L et al.Cancer genetics and cytogenetics. 2003, Vol 145, Num 1, pp 82-85, issn 0165-4608, 4 p.Article

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002RIZZIERI, David A; JOHNSON, Jeffrey L; LARSON, Richard A et al.British journal of haematology. 2014, Vol 165, Num 1, pp 102-111, issn 0007-1048, 10 p.Article

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia : a Cancer and Leukemia Group B (CALGB) studyLANGER, Christian; RADMACHER, Michael D; POWELL, Bayard L et al.Blood. 2008, Vol 111, Num 11, pp 5371-5379, issn 0006-4971, 9 p.Article

MicroRNA Expression in Cytogenetically Normal Acute Myeloid LeukemiaMARCUCCI, Guido; RADMACHER, Michael D; LIU, Chang-Gong et al.The New England journal of medicine. 2008, Vol 358, Num 18, pp 1919-1928, issn 0028-4793, 10 p.Article

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B studyFARAG, Sherif S; RUPPERT, Amy S; STAMBERG, Judith et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 482-493, issn 0732-183X, 12 p.Article

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of cancer and leukemia group B study 9251RIZZIERI, David A; JOHNSON, Jeffrey L; CANELLOS, George P et al.Cancer. 2004, Vol 100, Num 7, pp 1438-1448, issn 0008-543X, 11 p.Article

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemiaWALTER, Roland B; MEDEIROS, Bruno C; POWELL, Bayard L et al.Haematologica (Roma). 2012, Vol 97, Num 5, pp 739-742, issn 0390-6078, 4 p.Article

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML, within the ELN Favorable genetic categoryMETZELER, Klaus H; BECKER, Heiko; POWELL, Bayard L et al.Blood. 2011, Vol 118, Num 26, pp 6920-6929, issn 0006-4971, 10 p.Article

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBECKER, Heiko; MARCUCCI, Guido; WU, Yue-Zhong et al.Blood. 2010, Vol 116, Num 5, pp 788-792, issn 0006-4971, 5 p.Article

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular ResponsesCORTES, Jorge E; KANTARJIAN, Hagop M; SALVADO, August et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4754-4759, issn 0732-183X, 6 p.Article

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621KOLITZ, Jonathan E; GEORGE, Stephen L; CALIGIURI, Michael A et al.Journal of clinical oncology. 2004, Vol 22, Num 21, pp 4290-4301, issn 0732-183X, 12 p.Article

Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT₃₈₈GMCSF) for refractory or relapsed acute myeloid leukemiaFRANKEL, Arthur E; POWELL, Bayard L; HALL, Philip D et al.Clinical cancer research. 2002, Vol 8, Num 5, pp 1004-1013, issn 1078-0432Article

Bone marrow cytogenetic abnormalities of aplastic anemiaKEUNG, Yi-Kong; PETTENATI, Mark J; CRUZ, Julia M et al.American journal of hematology. 2001, Vol 66, Num 3, pp 167-171, issn 0361-8609Article

Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic PhaseNICOLINI, Franck E; TURKINA, Anna; SHEN, Zhi-Xiang et al.Cancer. 2012, Vol 118, Num 1, pp 118-126, issn 0008-543X, 9 p.Article

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyMETZELER, Klaus H; MAHARRY, Kati; WU, Yue-Zhong et al.Journal of clinical oncology. 2011, Vol 29, Num 10, pp 1373-1381, issn 0732-183X, 9 p.Article

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyLANGER, Christian; MARCUCCI, Guido; POWELL, Bayard L et al.Journal of clinical oncology. 2009, Vol 27, Num 19, pp 3198-3204, issn 0732-183X, 7 p.Article

Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B StudyPASCHKA, Peter; MARCUCCI, Guido; BAER, Maria R et al.Journal of clinical oncology. 2008, Vol 26, Num 28, pp 4595-4602, issn 0732-183X, 8 p.Article

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16) : A cancer and leukemia group B studyMARCUCCI, Guido; MROZEK, Krzysztof; STERLING, Lisa J et al.Journal of clinical oncology. 2005, Vol 23, Num 24, pp 5705-5717, issn 0732-183X, 13 p.Article

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age : Cancer and Leukemia Group B Study 9222MOORE, Joseph O; GEORGE, Stephen L; SCHIFFER, Charles A et al.Blood. 2005, Vol 105, Num 9, pp 3420-3427, issn 0006-4971, 8 p.Article

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B studyKORNBLITH, Alice B; HERNDON, James E; SCHIFFER, Charles A et al.Journal of clinical oncology. 2002, Vol 20, Num 10, pp 2441-2452, issn 0732-183XArticle

High frequency of immunophenotype changes in acute myeloid leukemia at relapse : implications for residual disease detection (Cancer and Leukemia Group B Study 8361)BAER, Maria R; STEWART, Carleton C; STONE, Richard M et al.Blood. 2001, Vol 97, Num 11, pp 3574-3580, issn 0006-4971Article

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineSTONE, Richard M; BERG, Deborah T; BLOOMFIELD, Clara D et al.Blood. 2001, Vol 98, Num 3, pp 548-553, issn 0006-4971Article

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502ATTAR, Eyal C; JOHNSON, Jeffrey L; BLUM, William et al.Journal of clinical oncology. 2013, Vol 31, Num 7, pp 923-929, issn 0732-183X, 7 p.Article

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBECKER, Heiko; MAHARRY, Kati; CARTER, Thomas H et al.Haematologica (Roma). 2011, Vol 96, Num 10, pp 1488-1495, issn 0390-6078, 8 p.Article